Hangzhou Coben Pharmaceutical Co., Ltd

Founded in 1997 and built to GMP standards, Coben Group operates across specialized chemical zones in Zhejiang Nanyang and Jiangsu Qidong spanning 110,000 square meters, specializing in developing and manufacturing APIs and intermediates for anti-AIDS, anti-cancer, cardiovascular and anti-inflammatory drugs. Main products include lamivudine, tenofovir, zidovudine, abacavir, emtricitabine, losartan, valsartan, irbesartan, clopidogrel, gemcitabine, carvedilol and capecitabine, with the company producing 500 MT annually of cytosine, the largest output worldwide. Coben is a state and provincial high-tech enterprise with its own R&D center, holding national and international patents for many self-developed products.